Figure 6.

After intraocular injection, AXT107 localizes to type 3 choroidal neovascularization (NV) in which cells stain for α_vβ₃ and α₅β₁

At P20, rho/VEGF mice were given an intravitreous injection of 1 μg of AXT107 (n = 10, A-L) or FAM-labeled AXT107 (n = 10, M-R). After 24 h retinal flat mounts or ocular sections were stained with FITC-Griffonia Simplicifolia Agglutinin (GSA) lectin (A and J) or Alexa Fluor 594-GSA (D, G, M, and P). Retinal flat mounts immunostained for α_vβ₃ (A–C), α₅β₁ (D–F) or AXT107 (G–I), showed staining for each within GSA-labeled buds of NV. Ocular sections also showed FITC-GSA-labeled NV that immunostained for AXT107 (J–L). Ocular sections (M−O) and retinal flat mounts (P–R) from eyes of P21 rho/VEGF mice that had been given an intravitreous injection of 1 μg of fluorescein amidite (FAM)-labeled AXT107 24 h before showed FAM-AXT107 in close association with Alexa Fluor 594-GSA-labeled type 3 choroidal NV (O and R). The study was conducted in duplicates, and qualitatively similar results were found in the replicates. Scale bars = 100 μm.